Rapid neuronal inhibition in the brain is mediated by γ-aminobutyric acid (GABA) activation of GABA
A receptors. The
GABRA5 gene, which encodes the α5 subunit of the GABA
A receptor, has been implicated in an aggressive subgroup of medulloblastoma (MB), a type of
[...] Read more.
Rapid neuronal inhibition in the brain is mediated by γ-aminobutyric acid (GABA) activation of GABA
A receptors. The
GABRA5 gene, which encodes the α5 subunit of the GABA
A receptor, has been implicated in an aggressive subgroup of medulloblastoma (MB), a type of pediatric brain tumor. However, the possible role of GABA
A receptor subunits in glioma remains poorly understood. Here, we examined the expression of genes encoding GABA
A receptor subunits in different types of glioma, and its possible association with patient prognosis assessed by overall survival (OS). Data were obtained from the French and The Cancer Genome Atlas Brain Lower Grade Glioma (TCGA-LGG) datasets and analyzed for expression of GABA
A receptor subunit genes. OS was calculated using the Kaplan–Meier estimate. We found that genes
GABRA2,
GABRA3,
GABRB3,
GABRG1, and
GABRG2 showed a significant association with OS, with higher gene expression indicating better prognosis. In patients with GBM, high expression of
GABRA2 was associated with shorter OS, whereas, in contrast, higher levels of
GABRB3 were associated with better prognosis indicated by longer OS. In patients with lower grade gliomas,
GABRA3,
GABRB3,
GABRG1, and
GABRG2, were associated with longer OS. High
GABRB3 expression was related to longer survival when low grade glioma types were analyzed separately. Our results suggest an overall association between higher expression of most genes encoding GABA
A receptor subunits and better prognosis in different types of glioma. Our findings support the possibility that down-regulation of GABA
A receptors in glioma contributes to promoting tumor progression by reducing negative inhibition. These findings might contribute to further evaluation of GABA
A receptors as a therapeutic target in glioma.
Full article